Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite the fact that the adjuvant properties of the heat-labile enterotoxins of Escherichia coli(LT) and Vibrio cholerae(CT) have been known for more than 20 years, there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins. A number of attempts with various degrees of success have been made to reduce or eliminate the enterotoxicity of LT and CT so they can safely be used as oral adjuvants or immunogens. In this report we characterize the structural, enzymatic, enterotoxic, and adjuvant properties of a novel mutant of LT, designated LT(R192G/L211A), or dmLT. dmLT was not sensitive to trypsin activation, had reduced enzymatic activity for induction of cyclic AMP in Caco-2 cells, and exhibited no enterotoxicity in the patent mouse assay. Importantly, dmLT retained the ability to function as an oral adjuvant for a coadministered antigen (tetanus toxoid) and to elicit anti-LT antibodies.In vitro and in vivo data suggest that the reduced enterotoxicity of this molecule compared to native LT or the single mutant, LT(R192G), is a consequence of increased sensitivity to proteolysis and rapid intracellular degradation in mammalian cells. In conclusion, dmLT is a safe and powerful detoxified enterotoxin with the potential to function as a mucosal adjuvant for coadministered antigens and to elicit anti-LT antibodies without undesirable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, a double-mutant labile toxin (dmLT) derived from Escherichia coli is a potent adjuvant that can enhance immune responses to IPV [113,114,115,116].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundNew knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
Levine, M. M., Kaper, J. B., Black, R. E., & Clements, M. L. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.4.510-550.1983 · Cited by 636
Intestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18326 · Cited by 572 · cited 1×
“In intestinal epithelial cells, this induction of cAMP causes a disregulation of cAMP-sensitive ion transport mechanisms, inhibiting intracellular salt absorption, increasing electrolyte transport into the gut lumen, and creating an osmotic gradient favoring intestinal water secretion (12).”
BackgroundProtein Disulfide Isomerase Acts as a Redox-Dependent Chaperone to Unfold Cholera Toxin
Tsai, B., Rodighiero, C., Lencer, W. I., & Rapoport, T. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00289-6 · Cited by 483 · cited 3×
“Tsai et al. demonstrated that protein disulfide isomerase (PDI) in the lumen of the ER functions to disassemble and unfold CT (and presumably LT) once its A-chain has been proteolytically cleaved at Arg192 (38).”
BackgroundInfluentialIntestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318326 · Cited by 468
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350 · cited 5×
“chromatography in our laboratory as described previously (6, 8, 34).”
BackgroundMethodInfluentialSelf-citationClements, J. D., & Finkelstein, R. A. (1979) · Infection and Immunity · doi:10.1128/iai.24.3.760-769.1979 · Cited by 330 · cited 2×
“chromatography in our laboratory as described previously (6, 8, 34).”
MethodResultSelf-citationMichetti, P., Kreiss, C., Kotloff, K. L., Porta, N., Blanco, J., Bachmann, D., Herranz, M., Saldinger, P. F., Corthésy–Theulaz, I., Losonsky, G., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70063-6 · Cited by 310
Lewis, D. J. M., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006999 · Cited by 305 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundClements, J. D., Hartzog, N. M., & Lyon, F. L. (1988) · Vaccine · doi:10.1016/0264-410x(88)90223-x · Cited by 284 · cited 1×
“Despite the fact that the adjuvant properties of LT and CT have been known for more than 20 years (7, 11), there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins.”
BackgroundSelf-citation
Research works printed but not linked: 1
- 28. Oplinger, M. L., et al. 1997. Abstr. 37th Intersci. Conf. Antimicrob.
Cited by
Items 101–200 of 216
Seo, H., Lu, T., Mani, S., Bourgeois, A. L., Walker, R. I., Sack, D. A., & Zhang, W. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1649555 · Cited by 21
Choudhari, S. P., Pendleton, K. P., Ramsey, J. D., Blanchard, T. G., & Picking, W. D. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23643 · Cited by 20
Implications of enterotoxigenicEscherichia coligenomics for vaccine development
Sjöling, Å., von Mentzer, A., & Svennerholm, A. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.996553 · Cited by 23
“Such a molecule has been developed by Clements and collaborators, that is, a double-mutated LT molecule (dmLT) [33].”
BackgroundSukwa, N., Mubanga, C., Hatyoka, L. M., Chilyabanyama, O. N., Chibuye, M., Mundia, S., Munyinda, M., Kamuti, E., Siyambango, M., Badiozzaman, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.052 · Cited by 20
Therapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media
Novotny, L. A., Clements, J. D., & Bakaletz, L. O. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00090-15 · Cited by 19
“(dmLT) as the adjuvant (17), 10 g dmLT alone, or an equivalent volume”
BackgroundSelf-citationLiu, D., Guo, H. B., Zheng, W., Zhang, N., Wang, T., Wang, P., & Ma, X. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7423-x · Cited by 19
“LT and its mutants (LTm) are capable of enhancing the strong mucosal immune responses to co-administered antigens in many types of vaccines, and some of the non-toxic mutants have been entered into clinical trials (Leach et al. 2012; Norton et al. 2011; Sjokvist Ottsjo et al. 2013).”
BackgroundSato, T., Matsui, T., Takita, E., Kadoyama, Y., Makino, S., Kato, K., Sawada, K., & Hamabata, T. (2013) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0118 · Cited by 19
“Several studies have demonstrated that the B subunits of CT and LT are strong mucosal adjuvants [3, 8, 9, 17].”
BackgroundToprani, V. M., Sahni, N., Hickey, J. M., Robertson, G. A., Middaugh, C. R., Joshi, S. B., & Volkin, D. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.101 · Cited by 19
“For example, the adjuvanticity and antigenicity of dmLT with a tetanus toxoid antigen has been evaluated in mice by measuring serum anti-antigen IgG and serum anti-LT IgG levels, respectively [17].”
BackgroundMethodCrothers, J. W., Ross Colgate, E., Cowan, K. J., Dickson, D. M., Walsh, M., Carmolli, M., Wright, P. F., Norton, E. B., & Kirkpatrick, B. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.056 · Cited by 18
Self-citationValli, E., Baudier, R. L., Harriett, A. J., & Norton, E. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227047 · Cited by 18
“coli clones expressing recombinant protein as previously described [3, 18].”
MethodResultSelf-citationNovel Role for Animal Innate Immune Molecules: Enterotoxic Activity of a Snail Egg MACPF-Toxin
Giglio, M. L., Ituarte, S., Ibañez, A. E., Dreon, M. S., Prieto, E. D., Fernández, P. E., & Heras, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00428 · Cited by 18
Evolution of adjuvants across the centuries
Garçon, N., Hem, S. L., & Friede, M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00020-3 · Cited by 20
Immunogenicity of a West Nile Virus DIII-Cholera Toxin A2/B Chimera after Intranasal Delivery
Tinker, J., Yan, J., Knippel, R. J., Panayiotou, P., & Cornell, K. (2014) · Toxins · doi:10.3390/toxins6041397 · Cited by 21
“Safe and effective administration of CT and LTI-based vaccines by oral, sublingual, and transcutaneous routes has proven promising in mice and humans, and may also prove to be effective for DIII-CTA2/B [ 54, 91–97].”
BackgroundMaciel, M., Smith, M. A., Poole, S., Laird, R. M., Rollenhagen, J. E., Kaminski, R. W., Wenzel, H., Bourgeois, A. L., & Savarino, S. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224073 · Cited by 18
Vaccines against Bacterial Enteric Infections
Holmgren, J. R., & Levine, M. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00056-2 · Cited by 18
Rémot, A., Roux, X., Dubuquoy, C., Fix, J., Bouet, S., Moudjou, M., Eléouët, J., Riffault, S., & Petit‐Camurdan, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037722 · Cited by 19
“Significantly, a double LT mutant (dmLT) with even lower toxicity than LT(R192G) has been developed [54].”
BackgroundLalsiamthara, J., Kamble, N. M., & Lee, J. H. (2016) · Veterinary Research · doi:10.1186/s13567-016-0348-7 · Cited by 17
“The desired amino acid substitutions in the LTA subunit were glycine instead of arginine and alanine instead of leucine at positions 192 and 211, respectively [16].”
BackgroundInfluentialRamakrishnan, A., Joseph, S. S., Reynolds, N. D., Poncet, D., Maciel, M., Nunez, G., Espinoza, N., Nieto, M., Castillo, R., Royal, J. M., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.12.034 · Cited by 18
Motyka, N. I., Stewart, S. R., Hollifield, I. E., Kyllo, T. R., Mansfield, J. A., Norton, E. B., Clements, J. D., & Bitoun, J. P. (2021) · Infection and Immunity · doi:10.1128/iai.00707-20 · Cited by 17
“LTh and dmLT were purified as previously described (5).”
BackgroundMethodInfluentialSelf-citationMaldarelli, G. A., & Matz, H. C. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000321 · Cited by 17
“dmLT has been previously shown to be an effective adjuvant for mucosal vaccines directed against viral as well as bacterial pathogens [30-32].”
BackgroundInfluentialAn Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
Govea‐Alonso, D. O., Malla, A., Bolaños−Martínez, O. C., Vimolmangkang, S., & Rosales‐Mendoza, S. (2022) · Pharmaceuticals · doi:10.3390/ph15101298 · Cited by 16
“coli enterotoxin (LT, closely related to CT in sequence and mecha ism of action), which poss ss s adjuvanti ity but lacks toxicity [32].”
BackgroundMurine models for mucosal tolerance in allergy
Smole, U., Schabussová, I., Pickl, W. F., & Wiedermann, U. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.007 · Cited by 17
White, J. A., Haghighi, C., Brunner, J., Estrada, M., Lal, M., & Chen, D. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.09.003 · Cited by 15
“For reconstitution, each vial of dmLT was diluted with 0.7 mL water-for-injection to achieve a final dmLT concentration of 1 mg/mL. Purified A and B-subunits of dmLT and dmLT specific rabbit sera used in assay development were provided by Tulane University (Provided by Dr. John Clements, Tulane University, New Orleans…”
MethodInfluentialTemprana, C. F., Argüelles, M. H., Gutierrez, N. M., Barril, P. A., Esteban, L. E., Silvestre, D., Mandile, M. G., Glikmann, G., & Castello, A. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203700 · Cited by 16
Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant
Braga, C. J. M., Rodrigues, J. F., Medina-Armenteros, Y., Farinha-Arcieri, L. E., Ventura, A. M., Boscardin, S. B., Sbrogio-Almeida, M. E., & Ferreira, L. C. D. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00487 · Cited by 14
Designing Vaccines to Neutralize Effective Toxin Delivery by Enterotoxigenic Escherichia coli
Fleckenstein, J. M., & Sheikh, A. (2014) · Toxins · doi:10.3390/toxins6061799 · Cited by 14
“Mutant forms of LT have therefore been constructed [28] which are devoid of enterotoxic activity [29] but which retain the ability to stimulate antibodies against both subunits, as well as their respective contributions to LT-adjuvant activity [30].”
BackgroundHeggelund, J. E., Heim, J. B., Bajc, G., Hodnik, V., Anderluh, G., & Krengel, U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030703 · Cited by 15
“This strategy is currently probed in clinical trials with the second generation oral ETEC vaccine [34,35], which includes a CTB/LTB chimera as well as a double-mutated LT holotoxin [36].”
MethodNguyen, H.-N. P., Steede, N. K., Robinson, J. E., & Landry, S. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.082 · Cited by 14
“C57BL/6 mice (six- to eight-week-old females) were intranasally immunized by a single administration of 20 μg gp120 protein plus 5 μg of double mutant (R192G, L211A) heatlabile toxin as adjuvant [30].”
MethodHuman Mucosal IgA Immune Responses against Enterotoxigenic Escherichia coli
Riaz, S., Steinsland, H., & Hanevik, K. (2020) · Pathogens · doi:10.3390/pathogens9090714 · Cited by 15
Bauer, D. L., Bachnak, L., Limbert, V. M., Horowitz, R. M., Baudier, R. L., D’Souza, S. J., Immethun, V. E., Kurtz, J. R., Grant, S. B., & McLachlan, J. B. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200221 · Cited by 13
Akhtar, M., Basher, S. R., Nizam, N. N., Hossain, L., Bhuiyan, T. R., Qadri, F., & Lundgren, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220130 · Cited by 13
“Age, median (range), years 32 (18-55) 28 (18-39)”
Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC
Salvador-Erro, J., Pastor, Y., & Gamazo, C. (2025) · Toxins · doi:10.3390/toxins17020071 · Cited by 16
“This created the double mutant (dmLT), or LT(R192G/L211A), which has demonstrated notable adjuvant capabilities in various studies [107,108], including the oral multivalent attenuated vaccine ACE527 [109], the inactivated ETEC vaccine ETVAX [110] and the subunit intramuscular vaccine targeting CS6…”
Deng, G., Zeng, J., Jian, M., Liu, W., Zhang, Z., Liu, X., & Wang, Y. (2012) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2012.09.009 · Cited by 13
Zeinalzadeh, N., Salmanian, A. H., Goujani, G., Amani, J., Ahangari, G., Akhavian, A., & Jafari, M. (2017) · Microbiology and Immunology · doi:10.1111/1348-0421.12491 · Cited by 13
Prior, J. T., Limbert, V. M., Horowitz, R. M., D’Souza, S. J., Bachnak, L., Godwin, M. S., Bauer, D. L., Harrell, J. E., Morici, L. A., Taylor, J. J., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00677-z · Cited by 13
“We chose to immunize orally due to the substantial body of literature that dmLT can act as an adjuvant in both mice and humans via the oral route 43 – 47 .”
Albert, M. J., Haridas, S., Ebenezer, M., Raghupathy, R., & Khan, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142090 · Cited by 13
“Clements, Tulane University Medical Center, New Orleans, LA [18].”
BackgroundInfluentialPreparing an Adjuvanted Thermoresponsive Gel Formulation for Sublingual Vaccination
Lal, M., White, J. A., & Zhu, C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6445-1_11 · Cited by 14
Zeinalzadeh, N., Salmanian, A. H., Ahangari, G., Sadeghi, M., Amani, J., Bathaie, S. Z., & Jafari, M. (2013) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1196 · Cited by 13
RetractedLalsiamthara, J., & Lee, J. H. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.12.042 · Cited by 14
Motyka, N. I., Stewart, S. R., Porretta, C. P., Hollifield, I. E., Bauer, D. L., & Bitoun, J. P. (2022) · Infection and Immunity · doi:10.1128/iai.00637-21 · Cited by 14
“LTh, LTA, LTB, dmLT, and E112K were purified as previously published (30).”
BackgroundMethodMubanga, C., Simuyandi, M., Mwape, K., Chibesa, K., Chisenga, C. C., Chilyabanyama, O. N., Randall, A. Z., Liang, X., Glashoff, R. H., & Chilengi, R. (2023) · Vaccines · doi:10.3390/vaccines11050939 · Cited by 12
Estupiñan, J. L. M., Pind, A. A. A., Pajoohian, P. F., Jónsdóttir, I., & Bjarnarson, S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1078904 · Cited by 11
“The adjuvants mmCT and dmLT were produced as described previously (30, 31) and provided by the Vaccine Research Institute (University of Gothenburg, Sweden).”
BackgroundMethodNon-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants
Han, S., Lee, P., & Choi, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082114 · Cited by 13
“• Subunit vaccine [278] Clostridium tetani In preclinical”
BackgroundOral inactivated whole cell vaccine for mucosal immunization: ETVAX case study
Walker, R. I., & Bourgeois, A. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125102 · Cited by 12
“To further enhance the immunogenicity of the vaccine, it was combined with the double mutant labile toxin of ETEC (dmLT) adjuvant (10, 14, 15).”
BackgroundTerrinoni, M., Holmgren, J. R., Lebens, M., & Larena, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-38726-0 · Cited by 11
Toprani, V. M., Hickey, J. M., Sahni, N., Toth, R. T., Robertson, G. A., Middaugh, C. R., Joshi, S. B., & Volkin, D. B. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.07.019 · Cited by 11
Mechanisms of Cholera Toxin in the Modulation of TH17 Responses
Tsai, H., & Wu, R. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2015012295 · Cited by 12
Gutiérrez, R. L., Riddle, M. S., Porter, C. K., Maciel, M., Poole, S., Laird, R. M., Lane, M., Turiansky, G. W., Jarell, A. D., & Savarino, S. J. (2023) · Microorganisms · doi:10.3390/microorganisms11112689 · Cited by 10
“We co-administered each dscCfaE antigen with mLT, which has been shown to help potentiate mucosal responses [30,31].”
MethodKim, S., Shim, E.-H., Kim, D., & Jang, Y. (2023) · npj Vaccines · doi:10.1038/s41541-023-00720-z · Cited by 9
“Approaches to developing mucosal vaccine adjuvants have focused on potentiating the immune response induced by subunit vaccines using enterotoxin-derived adjuvants or invariant natural killer T cell activators 13,14 .”
Providing Structure to Enterotoxigenic Escherichia coli Vaccine Development
Fleckenstein, J. M. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix146 · Cited by 9
“Incorporation of emerging recombinant toxoids [27], including mutant forms of heat-labile toxin, which can also serve as a potent mucosal adjuvant [28], and more recently discovered antigens [29] from the ETEC pathovar could potentially complement the tip adhesin approach.”
BackgroundRecent progress in enterotoxigenic Escherichia coli vaccine research and development
Zhang, W., & Sack, D. A. (2025) · Infection and Immunity · doi:10.1128/iai.00368-25 · Cited by 8
“Compared to a single mutant LT, mLT or LT R192G , the dmLT showed further enterotoxicity reduction (78).”
Borde, A., Ekman, A., Larsson, A., Carlin, N., Holmgren, J. R., & Tobias, J. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.07.011 · Cited by 8
Stone, A. E., Rambaran, S., Trinh, I., Estrada, M., Jarand, C. W., Williams, B. S., Murrell, A. E., Huerter, C. M., Bai, W. H., Palani, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.033 · Cited by 8
“coli (ETEC) LT-R192G/L211A or dmLT [3, 4].”
BackgroundMethodInfluentialSelf-citationWestcott, M. M., Blevins, M. W., Wierzba, T. F., Morse, A. E., White, K. R., Sanders, L. A., & Sanders, J. W. (2023) · Microorganisms · doi:10.3390/microorganisms11082040 · Cited by 12
“There are obvious implications, including the potential for toxin production to cause adverse effects, which could be addressed using strains with mutations that detoxify but leave the intrinsic antigenicity and adjuvant activity of LT intact [30,31].”
BackgroundInfluentialGonçalves, E., Guillén, Y., Lama, J. R., Sánchez, J., Brander, C., Paredes, R., & Combadière, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657162 · Cited by 11
“The first observation of a potential link between the microbiome and vaccines occurred in an oral vaccination model that used a heat-labile enterotoxin from Escherichia coli as an adjuvant (5, 6).”
BackgroundHossain, M. J., Svennerholm, A., Carlin, N., D’Alessandro, U., & Wierzba, T. F. (2023) · Microorganisms · doi:10.3390/microorganisms12010090 · Cited by 7
“A double amino acid mutant of LT, dmLT, was also added to the vaccine as a mucosal adjuvant [21] to enhance antitoxin and anti-CF immunity.”
BackgroundZhang, C., Li, S., Upadhyay, I., Lauder, K. L., Sack, D. A., & Zhang, W. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04153-23 · Cited by 7
Coria, L. M., Martinez, F. L., Bruno, L. A., Pasquevich, K. A., & Cassataro, J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.039 · Cited by 7
Vaccine Candidate Double Mutant Variants of Enterotoxigenic Escherichia coli Heat-Stable Toxin
Zegeye, E. D., Díaz, Y., & Puntervoll, P. (2022) · Vaccines · doi:10.3390/vaccines10020241 · Cited by 7
“5 μg mutant STh peptide, with 1 μg of the double mutant heat-labile toxin (dmLT) adjuvant [31].”
MethodInfluentialFreytag, L. C., & Clements, J. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00061-6 · Cited by 11
Self-citationConserved antigens for enteric vaccines
Walker, R. I. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126828 · Cited by 7
“In addition to offering antitoxin protection against acute and long-term effects of ETEC infection, LT is un i que in that it is not only a potent antitoxin component for a future ETEC vaccine, but it is also an effective mucosal adjuvant [65,66].”
Bhuiyan, T. R., Khanam, F., Basher, S. R., Dash, P., Chowdhury, M. I., Haque, S., Harun, N. B., Akter, A., Karmakar, P. C., Hakim, A., et al. (2025) · Frontiers in Bacteriology · doi:10.3389/fbrio.2025.1567791 · Cited by 6
“A second-generation derivative, double-mutant LT [dmLT or LT(R192G/L211A)] was created with no enterotoxicity for further human study evaluation (Norton et al., 2011).”
Martín-Martín, A., Tejedor, L., Tafalla, C., & Díaz‐Rosales, P. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.07.016 · Cited by 6
Detecting Glucose Fluctuations in the Campylobacter jejuni N-Glycan Structure
Nothaft, H., Bian, X., Shajahan, A., Miller, W. G., Bolick, D. T., Guerrant, R. L., Azadi, P., Ng, K. K.-S., & Szymanski, C. M. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00498 · Cited by 6
Dièye, Y., Nguer, C. M., Thiam, F., Diouara, A. A. M., & Fall, C. (2022) · Antibiotics · doi:10.3390/antibiotics11121701 · Cited by 6
Sahni, N., Cheng, Y. G., Middaugh, C. R., & Volkin, D. B. (2016) · Wiley eBooks · doi:10.1002/9781118833322.ch24 · Cited by 7
Immunomodulatory effects of gut microbiota on vaccine efficacy against respiratory pathogens
Li, X., Wang, C., & Liu, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618921 · Cited by 7
Duan, Q., Pang, S., Feng, L., Li, B., Lv, L., Liang, Y., & Zhu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021245 · Cited by 5
“1% of the enzymatic activity of LT [25].”
BackgroundGut Immunology and Oral Vaccination
Tennant, S. M., Muhsen, K., & Pasetti, M. F. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1419-3_3 · Cited by 6
Terrinoni, M., Holmgren, J. R., Turbyfill, K. R., Verg, L. V. D., Maier, N., & Walker, R. W. (2025) · Vaccines · doi:10.3390/vaccines13050513 · Cited by 5
“Further, the mucosal adjuvant double-mutant heat-labile toxin (dmLT) [24,25] has been used in numerous vaccine studies to improve both systemic and mucosal immune responses against enteric pathogens, including to the most advanced ETEC vaccine candidate, ETVAX.”
Estupiñan, J. L. M., Pajoohian, P. F., Pedersen, G. K., Christensen, D., Marchi, S., Montomoli, E., Bjarnarson, S. P., Jónsdóttir, I., & Pind, A. A. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646677 · Cited by 4
“The adjuvants (Supplementary Table S1) mmCT and dmLT were manufactured as previously described (35, 36) and provided by the Vaccine Research Institute (University of Gothenburg, Sweden).”
Human and Veterinary Vaccines against Pathogenic Escherichia coli
Larzábal, M., Cataldi, Á., & Vilte, D. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82835 · Cited by 4
GM‐CSF is key in the efficacy of vaccine‐induced reduction of Helicobacter pylori infection
Vaillant, L., Oster, P., McMillan, B., Fernandez, E. O., & Velin, D. (2022) · Helicobacter · doi:10.1111/hel.12875 · Cited by 4
Farsani, H. H., Rasooli, I., Gargari, S. L. M., Nazarian, S., & Astaneh, S. D. A. (2015) · World Journal of Methodology · doi:10.5662/wjm.v5.i4.230 · Cited by 4
Vaccination Against Helicobacter pylori Infection
Raghavan, S., & Quiding‐Järbrink, M. (2016) · Springer eBooks · doi:10.1007/978-4-431-55936-8_25 · Cited by 6
Immunomodulatory regulation by heat-labile enterotoxins and potential therapeutic applications
Knapp, M.-P. A., Johnson, T. A., Ritter, M. K., Rainer, R. O., Fiester, S. E., Grier, J. T., Connell, T. D., & Arce, S. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945449 · Cited by 4
Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies
Lee, W.-H., & Kim, E. (2026) · Biomedicines · doi:10.3390/biomedicines14051060 · Cited by 6
“The most potent mucosal adjuvants, CT and LT, are too toxic for clinical application, and while safer derivatives such as dmLT are advancing through clinical trials, none has been licensed [54,55].”
InfluentialHsieh, H.-C., Chen, C.-C., Chou, P.-H., Liu, W., & Wu, S. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105752 · Cited by 3
Vintiñi, E. (2012) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000153 · Cited by 3
“However, they are also very toxic and not acceptable for human use [5] despite attempts to overcome this drawback [6,7].”
Backgroundhe Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms
Nashar, T. O. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000225 · Cited by 3
The type 2 secretion and type 4 pilus systems of Escherichia coli
Masi, L. G. D., Sturey, C. D., Lieberman, J. A., & Donnenberg, M. S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397048-0.00013-9 · Cited by 3
Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy
Vaillant, L., Oster, P., McMillan, B., & Velin, D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.034 · Cited by 4
Approaches to Enhance and Evaluate the Immunogenicity of an Oral ETEC Vaccine
Leach, S. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 5
Vickers, T. J., Buckley, D. P., Khatoon, N., Sheikh, A., Setu, B., Berndsen, Z. T., & Fleckenstein, J. M. (2025) · Infection and Immunity · doi:10.1128/iai.00601-24 · Cited by 3
Glycolysis maintains effector function of lung Th17 TRM cells in precision cut lung slices
Yang, H., Kumaran, V. R., Song, K., Remcho, T. P., Clark, R. D. E., Thakur, S., Lu, S., Harrison, M. A. A., Iwanaga, N., García-Hernández, M. D. L. L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114051 · Cited by 2
Self-citationMaciel, M., Scott, J. C., Baudier, R. L., Clements, J. D., Laird, R. M., Gutiérrez, R. L., Porter, C. K., & Norton, E. B. (2025) · Medical Microbiology and Immunology · doi:10.1007/s00430-025-00817-3 · Cited by 2
“Genetic mutations have been introduced to divorce the toxicity of the molecule from its immunogenicity and adjuvanticity, including molecules like LT-R192G (mLT), and LT-R192G/L211A (dmLT) [28, 29].”
Self-citationHarandi, A. M., & Lycke, N. Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00019-0 · Cited by 2
Modern Vaccine Adjuvant/Formulation—Session 9: Adjuvants
Dalençon, F. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26074 · Cited by 2
Giese, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-25832-4_9 · Cited by 2
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration
Estrada, M., Bzami, A., Norton, E. B., & White, J. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.005 · Cited by 2
“A monoclonal antibody (mAb; Precision Antibody, Columbia, MD) was developed against the A-subunit of dmLT for ELISA use.”
BackgroundSelf-citationShigella Mutant with Truncated O-Antigen as an Enteric Multi-Pathogen Vaccine Platform
Kim, J., Nothaft, H., Moon, Y., Jeong, S., Vortherms, A. R., Song, M., Szymanski, C. M., White, J. A., & Walker, R. I. (2025) · Vaccines · doi:10.3390/vaccines13050506 · Cited by 1
“The STM and STM-Cj were administered alone or with 5 µ g of dmLT produced by PATH [15].”
Immunogenicity and protection mediated by dmLT and alum adjuvants for an HIV-1 vaccine
Stokdyk, K., Sahoo, A., Gangadhara, S., Williams, L. D., Styles, T. M., Hellman, C. A., Zhang, L., Odeh, A. J., Flaherty, S., Shen, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1706958 · Cited by 1
“DmLT is a derivative of enterotoxigenic Escherichia coli ’ s heat-labile toxin and has primarily been used in mucosal vaccines against diarrheal diseases, including in at least 10 human trials (30 – 32).”
Self-citationBourgeois, A. L., Scott, D. A., Baqar, S., Tribble, D. R., Svennerholm, A., & Walker, R. I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805998 · Cited by 1
“LTR192G/L211A is termed double-mutant LT, or dmLT (15, 16). dmLT has signi fi cantly reduced enterotoxicity compared to nLT while retaining the adjuvant properties of the nLT (15, 16, 34). dmLT promotes antigen-speci fi c responses, including Th1, Th2, Th17, cytotoxic T lymphocytes, and antibodies.”
Therapeutics and Vaccines Against Pathogenic Escherichia coli
Palermo, M. S., Flores‐Figueroa, J., & Paredes‐Paredes, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-45092-6_11 · Cited by 1
Hsieh, H.-C., Chen, C.-C., Liu, W., & Wu, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126448 · Cited by 1
Edao, B. M., Upadhyay, I., & Zhang, W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127634 · Cited by 1
Peptide Vaccines for Otitis Media
Novotny, L. A., & Bakaletz, L. O. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00082-8 · Cited by 1
Liu, D., Zhang, N., Zheng, W., Guo, H. B., Wang, X., Wang, T., Wang, P., & Ma, X. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-015-1977-4 · Cited by 1
Holmgren, J. R., & Lundgren, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00018-3 · Cited by 2
Ferreira Luis, C. S., Cintra, M. D. J., Maeda, D. L. N. F., Mathias-Santos, C., Pereira, L. R., Luiz, W. B., & Rodrigues, J. F. (2018) · International Journal of Vaccine Research · doi:10.15226/2473-2176/3/1/00125 · Cited by 1
“However, the inherent toxicity of LT, even after inoculation of low amounts, has precluded its use as a vaccine adjuvant for humans, particularly under mucosal route[3,4,7,8].”
Background
Metadata
- Authors
- Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D.
- Affiliations
- Tulane University (US)
- Corresponding author
- Clements, John D.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2011-02-02
- Volume
- 18
- Issue
- 4
- Pages
- 546-551
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- PMC
- PMC3122563
- OpenAlex
- W2133080338
- Cited by
- 221
- References
- 40
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 2 · 2023: 25 · 2022: 8 · 2021: 10 · 2020: 13 · 2019: 14 · 2018: 20 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 18 · 2013: 17 · 2012: 16
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Clinical and Vaccine Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Louisiana Board of Regents
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering (EB006493-04, R01EB006493)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- heat-labile enterotoxin, Escherichia coli, oral adjuvant, trypsin activation, enterotoxicity, tetanus toxoid, mucosal immunization, intracellular degradation, proteolysis
- MeSH terms
- Adjuvants, Immunologic, Administration, Oral, Animals, Antibodies, Bacterial, Antitoxins, Bacterial Toxins, Enterotoxins, Female, Humans, Mice, Inbred BALB C, Tetanus Toxoid, Caco-2 Cells, Amino Acid Substitution, Escherichia coli Proteins, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.